<DOC>
	<DOCNO>NCT00332033</DOCNO>
	<brief_summary>Uterine leiomyoma ( fibroid ) represent major public health problem effective therapy . Currently , definitive treatment hysterectomy woman demand alternative therapy surgery . We develop new approach treatment uterine fibroid base collaborative laboratory research molecular , ultra-structural , histopathologic change occur transformation normal uterine myocytes abnormal myocytes comprise uterine fibroid . We confirm excessive , dysregulated collagen production ( fibrosis ) abnormal collagen deposition underlie etiology pathogenesis leiomyoma . We test hypothesis anti-tumor drug ( Pirfenidone ) decrease size clinically relevant leiomyomas 30 % . The specific aim compare effect pirfenidone placebo uterine leiomyoma volume . Thirty-two ( 32 ) woman randomize double-blinded treatment design . Inclusion criterion include woman complete child-bearing , candidate hysterectomy , use effective contraceptive , least one uterine leiomyoma great 4 cm diameter confirm ultrasound . Women exclude body mass index great 33 kg/m ( 2 ) , gynecological disease , history cardiovascular disease smoking . Response treatment group assess T-2 weight magnetic resonance imaging ( MRI ) 3-D ultrasound image study enrollment period . To knowledge , first study document response large fibroid short-term trial anti-tumor drug . The data use define role fibrosis leiomyoma establish clinical trial thoroughly evaluate therapeutic approach uterine leiomyoma .</brief_summary>
	<brief_title>Development Non-Invasive Treatment Uterine Leiomyoma ( Fibroids )</brief_title>
	<detailed_description>Uterine leiomyoma ( fibroid ) represent major public health problem effective therapy . Currently , definitive treatment hysterectomy woman demand alternative therapy surgery . We develop new approach treatment uterine fibroid base collaborative laboratory research molecular , ultra-structural , histopathologic change occur transformation normal uterine myocytes abnormal myocytes comprise uterine fibroid . We confirm excessive , dysregulated collagen production ( fibrosis ) abnormal collagen deposition underlie etiology pathogenesis leiomyoma . We test hypothesis anti-tumor drug ( Pirfenidone ) decrease size clinically relevant leiomyomas 30 % . The specific aim compare effect pirfenidone placebo uterine leiomyoma volume . Thirty-two ( 32 ) woman randomize double-blinded treatment design . Inclusion criterion include woman complete child-bearing , candidate hysterectomy , use effective contraceptive , least one uterine leiomyoma great 4 cm diameter confirm ultrasound . Women exclude body mass index great 33 kg/m ( 2 ) , gynecological disease , history cardiovascular disease smoking . Response treatment group assess T-2 weight magnetic resonance imaging ( MRI ) 3-D ultrasound image study enrollment period . To knowledge , first study document response large fibroid short-term trial anti-tumor drug . The data use define role fibrosis leiomyoma establish clinical trial thoroughly evaluate therapeutic approach uterine leiomyoma .</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<mesh_term>Pirfenidone</mesh_term>
	<criteria>INCLUSION CRITERIA : Parous nonparous woman complete childbearing ( age criterion great 35 yearsold , less 50 yearsold ) . Currently practice willing practice contraception throughout duration study . Women least one fibroid great 4 cm diameter ultrasound examination . Women plan undergo hysterectomy treatment symptomatic fibroid may also participate willing defer operation study complete . The patient understand may choose surgery nonstudy treatment time enrollment end study participation . EXCLUSION CRITERIA : Inability comply study visit requirement . BMI great 33kg/m ( 2 ) History serious adverse reaction study medication . Inability tolerate MRI 3D ultrasound procedure ( i.e . presence intrauterine device ( IUD ) , pacemaker , aneurismal clip metallic device compatible magnetic resonance imaging ) . Medical problem include : genetic disease cause fibroid , history thromboembolic ( blood clot ) event need anticoagulation ( Coumadin , Heparin , etc. ) . A history cancer within past 5 year . Abnormal liver function test ( typically , great 20 % elevation ) . Mild elevation discretion investigator , undiagnosed liver condition represent exclusion criterion . Pregnancy lactation . Pregnancy evaluate ( Beta ) hCG test every 30 day . Patients ask use nonhormonal contraception method study drug . Severe anemia ( hct . Less 30 ) . Mild anemia common woman fibroid . Recent rapid growth fibroid ( i.e . double size within onesix month ) . Use following medication : 1 . Oral , injectable , inhaled steroid megesterol within past year 2 . Estrogen progesteronecontaining compound ( include oral contraceptive , hormone replacement therapy , transdermal/injectable/vaginal/oral preparation , herbal medication estrogenic antiestrogenic effect ) within past 812 week ; GnRH analog ( Danazol ) compound affect menstrual cyclicity 3 . Agents like Imidazoles , due possible interference metabolism . Unevaluated gynecologic abnormality ( unexplained vaginal bleeding , cervical dysplasia , abnormal adnexal/ovarian mass ) .</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 16, 2007</verification_date>
	<keyword>Fibroids</keyword>
	<keyword>Leiomyoma</keyword>
	<keyword>Pirfenidone</keyword>
	<keyword>Misoprostol</keyword>
	<keyword>Non-Surgical</keyword>
	<keyword>Collagen</keyword>
	<keyword>Uterus</keyword>
	<keyword>Uterine Fibroids</keyword>
	<keyword>Uterine Leiomyoma</keyword>
</DOC>